{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:38:52Z","timestamp":1784831932280,"version":"3.55.0"},"reference-count":95,"publisher":"Radcliffe Medical Media Ltd","issue":"2","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Interv Cardiol"],"abstract":"<jats:p>Cardiovascular disease and cancer are leading contributors to the global disease burden. As a result of cancer therapy-related cardiotoxicities, cardiovascular disease results in significant morbidity and mortality in cancer survivors and patients with active cancer. There is an unmet need for management of cardio-oncology conditions, which is predicted to reach epidemic proportions, and better understanding of their pathophysiology and treatment is urgently required. The proposed mechanisms underlying cardiotoxicity induced by 5-fluorouracil (5-FU) are vascular endothelial damage followed by thrombus formation, ischaemia secondary to coronary artery vasospasm, direct toxicity on myocardium and thrombogenicity. In patients with angina and electrocardiographic evidence of myocardial ischaemia due to chemotherapy-related coronary artery vasospasm, termination of chemotherapy and administration of calcium channel blockers or nitrates can improve ischaemic symptoms. However, coronary artery vasospasm can reoccur with 5-FU re-administration with limited effectiveness of vasodilator prophylaxis observed. While pre-existing coronary artery disease may increase the ischaemic potential of 5-FU, cardiovascular risk factors do not appear to completely predict the development of cardiac complications. Pharmacogenomic studies and genetic profiling may help predict the occurrence and streamline the treatment of 5-FU-induced coronary artery vasospasm. Echocardiographic measures such as the Tei index may help detect subclinical 5-FU cardiotoxicity. Further research is required to explore the cardioprotective effect of agents such as coenzyme complex, GLP-1 analogues and degradation inhibitors on 5-FU-induced coronary artery vasospasm.<\/jats:p>","DOI":"10.15420\/icr.2019.12","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T09:41:47Z","timestamp":1558690907000},"page":"89-94","source":"Crossref","is-referenced-by-count":74,"title":["Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions"],"prefix":"10.15420","volume":"14","author":[{"given":"Jun Hua","family":"Chong","sequence":"first","affiliation":[{"name":"Cardio-Oncology Service, Barts Heart Centre, St Bartholomew\u2019s Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun K","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Service, Barts Heart Centre, St Bartholomew\u2019s Hospital, London, UK; Cardio-Oncology Service, University College London Hospital, Hatter Cardiovascular Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"ref0","unstructured":"1. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019;139:e56-e528."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Prevalence and prevention of cardiovascular disease and diabetes mellitus","DOI":"10.1016\/j.phrs.2016.09.040"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"The importance of registries in cancer control","DOI":"10.21149\/spm.v58i2.7802"},{"key":"ref3","unstructured":"4. WHO. Cancer. Geneva; WHO, 2018. Available at: https:\/\/www. who.int\/en\/news-room\/fact-sheets\/detail\/cancer (accessed 1 May 2019)."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Lucas G, Marcu A, Piano M, et al. Cancer survivors' experience with telehealth: a systematic review and thematic synthesis. J Med Internet Res 2017;19:e11.","DOI":"10.2196\/jmir.6575"},{"key":"ref5","unstructured":"6. Cancer Research UK. Available at: www.cancerresearchuk.org (accessed 24 April 2019)."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Cancer treatment and survivorship statistics","DOI":"10.3322\/caac.21149"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level","DOI":"10.1016\/j.jacc.2015.04.059"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Weaver KE, Foraker RE, Alfano CM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv Res Pract 2013;7:253-61.","DOI":"10.1007\/s11764-013-0267-9"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma","DOI":"10.1182\/blood-2005-08-3392"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Cardio-oncology - a new subspecialty with collaboration at its heart","DOI":"10.1016\/j.ihj.2017.05.006"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis","DOI":"10.1073\/pnas.1200419109"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pr 2011;2011:394740.","DOI":"10.4061\/2011\/394740"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Pericardial disease in cancer patients","DOI":"10.1007\/s11936-018-0654-7"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Chung R, Ghosh AK, Banerjee A. Cardiotoxicity: precision medicine with imprecise definitions. Open Heart 2018;5:e000774.","DOI":"10.1136\/openhrt-2018-000774"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Ischemic heart disease: special considerations in cardio-oncology","DOI":"10.1007\/s11936-017-0535-5"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Davignon J GP. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109(Suppl 1):11127-32.","DOI":"10.1161\/01.CIR.0000131515.03336.f8"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"An update on cardio-oncology","DOI":"10.1016\/j.tcm.2014.07.003"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Coronary artery spatial distribution of acute myocardial infarction occlusions","DOI":"10.1161\/01.CIR.0000135468.67850.F4"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"An emerging epidemic: cancer and heart failure","DOI":"10.1042\/CS20160412"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Ghosh AK, Walker JM. Cardio-oncology. Br J Hosp Med 2017;78:C11-3.","DOI":"10.12968\/hmed.2017.78.1.C11"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Iliescu CA, Grines CL, Herrmann J, et al. SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latinoamericana de Cardiolog\u00eda Intervencionista). Catheter Cardiovasc Interv 2016;87:E202-23.","DOI":"10.1002\/ccd.26375"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Sorafenib-associated multivessel coronary artery vasospasm","DOI":"10.1007\/s00059-011-3444-5"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina","DOI":"10.1111\/j.1445-5994.2009.02144.x"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","DOI":"10.2165\/00002018-200022040-00002"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil","DOI":"10.1093\/annonc\/mdf108"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","DOI":"10.1186\/2050-6511-15-47"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","DOI":"10.1007\/s00432-007-0250-9"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"The prodrugs of 5-fluorouracil","DOI":"10.2174\/1568011023354146"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","DOI":"10.1007\/s00280-005-0178-1"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Clinical and electrocardiography changes in patients treated with capecitabine","DOI":"10.1159\/000331645"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","DOI":"10.1016\/j.ejca.2005.03.027"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Acute coronary syndrome induced by oral capecitabine","DOI":"10.1016\/S0828-282X(06)70905-9"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Coughlin S, Das S, Lee J, Cooper J. Capecitabine induced vasospastic angina. Int J Cardiol 2008;130:e34-6.","DOI":"10.1016\/j.ijcard.2007.06.152"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil","DOI":"10.1093\/annonc\/mdf035"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","DOI":"10.1016\/j.ctrv.2013.03.005"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history","DOI":"10.1016\/j.ejca.2013.03.004"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Fluoropyrimidine-associated cardiotoxicity: revisited","DOI":"10.1517\/14740330902733961"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"A planned surveillance study with 102 patients","DOI":"10.1159\/000072334"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Acute coronary syndrome secondary to fluorouracil infusion","DOI":"10.1200\/JCO.2005.04.0766"},{"key":"ref40","unstructured":"41. Fajardo LF, Stewart JR. Pathogenesis of radiation-induced myocardial fibrosis. Lab Invest 1973;29:244-55."},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. May D, Wandl U, Becher R, et al. Cardiac side effects of 5-fluorouracil. Dtsch Med Wochenschr 1990;115:618-21 [in German].","DOI":"10.1055\/s-2008-1065055"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"5-fluorouracil induces arterial vasocontractions","DOI":"10.1093\/annonc\/mdh150"},{"key":"ref43","unstructured":"44. Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit 2002;8:P151-7."},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","DOI":"10.1177\/030089168206800609"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","DOI":"10.1200\/JCO.1992.10.11.1795"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Fluorouracil cardiotoxicity","DOI":"10.1177\/106002809402800314"},{"key":"ref47","unstructured":"48. Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit Int Med J Exp Clin Res 2002;8:P151-7."},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"5-fluorouracil-associated cardiotoxicity","DOI":"10.1002\/1097-0142(19880101)61:1<36::AID-CNCR2820610108>3.0.CO;2-6"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity","DOI":"10.1007\/s00280-011-1669-x"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation","DOI":"10.1002\/sca.4950230101"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction","DOI":"10.1097\/MBC.0b013e3283597605"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"A case of severe coronary spasm associated with 5-fluorouracil chemotherapy","DOI":"10.3904\/kjim.2012.27.3.342"},{"key":"ref53","unstructured":"54. Tsiamis E, Synetos A, Stefanidis C. Capecitabine may induce coronary artery vasospasm. Hellenic J Cardiol 2012;53:320-3."},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm","DOI":"10.1177\/1078155211399164"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity of 5-fluorouracil","DOI":"10.2174\/187152506775268785"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"5-fluorouracil-induced coronary vasospasm","DOI":"10.1177\/107327480401100107"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Coronary artery spasm induced by 5-fluorouracil","DOI":"10.1093\/oxfordjournals.eurheartj.a059919"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels","DOI":"10.1007\/s12032-009-9226-8"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"5-fluorouracil induces arterial vasocontractions","DOI":"10.1093\/annonc\/mdh150"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"61. Cwikiel M, Zhang B, Eskilsson J, et al. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995;9:561.","DOI":"10.1016\/0959-8049(95)95370-L"},{"key":"ref61","unstructured":"62. Cwikiel M, Eskilsson J, Wieslander JB, et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996;10:805."},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Cardiovascular effects of systemic cancer treatment","DOI":"10.1016\/j.ctrv.2010.11.001"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease","DOI":"10.1161\/01.CIR.0000105763.51286.7F"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"65. Fleming I, Fisslthaler B, Dimmeler S, et al. Phosphorylation of Thr(495) regulates Ca(2+)\/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 2001;88:E68-75.","DOI":"10.1161\/hh1101.092677"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation","DOI":"10.1038\/21224"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Very high endothelin plasma levels in patients with 5-FU cardiotoxicity","DOI":"10.1093\/oxfordjournals.annonc.a058084"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Endothelins","DOI":"10.1056\/NEJM199508103330607"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Endothelin - biology and disease","DOI":"10.1016\/j.cellsig.2010.05.002"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone","DOI":"10.1016\/S0735-1097(00)01042-1"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries","DOI":"10.1161\/hc3501.095707"},{"key":"ref71","unstructured":"72. Mosseri M, Fingert HJ, Varticovski L, et al. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res 1993;53:3028-33."},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"The endothelial cell in health and disease: its function, dysfunction, measurement and therapy","DOI":"10.1038\/ijir.2009.59"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7","DOI":"10.1263\/jbb.106.248"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes","DOI":"10.1007\/s10557-014-6538-5"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"76. Chen J, Cha-Molstad H, Szabo A, Shalev A. Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab 2009;296:E1133-9.","DOI":"10.1152\/ajpendo.90944.2008"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Preventing beta-cell loss and diabetes with calcium channel blockers","DOI":"10.2337\/db11-0955"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","DOI":"10.1007\/s00432-007-0250-9"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Cardiac side effects of chemotherapy: State of art and strategies for a correct management","DOI":"10.2174\/157016111201140327163302"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"5-fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators","DOI":"10.1097\/00000441-198710000-00004"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","DOI":"10.1200\/JCO.1989.7.4.509"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Prophylaxis of 5-fluorouracil-induced coronary vasopasm with calcuim channel blockers","DOI":"10.1016\/S0002-9343(88)80268-7"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report","DOI":"10.1186\/1471-2261-1-3"},{"key":"ref83","unstructured":"84. Keefe D. Cardiovascular emergencies in the cancer patient. Semin Oncol 2000;27:244."},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil","DOI":"10.1016\/S0002-9343(01)00808-7"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"A case of coronary spasm induced by 5-fluorouracil","DOI":"10.2143\/AC.57.5.2005458"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Calcium-antagonist drugs","DOI":"10.1056\/NEJM199911043411907"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Prinzmetal's angina during 5-fluorouracil chemotherapy","DOI":"10.1016\/0002-9343(87)90465-7"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Improving adjuvant therapy for rectal cancer by combing protracted-infusion fluorouracil with radiation therapy after curative surgery","DOI":"10.1056\/NEJM199408253310803"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report","DOI":"10.1007\/s002800050877"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Coenzyme complex decreased cardiotoxicity when combined with chemotherapy in treating elderly patients with gastrointestinal cancer","DOI":"10.7314\/APJCP.2015.16.9.4045"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1","DOI":"10.1111\/bph.13725"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Training enhances vascular relaxation after chemotherapy-induced vasoconstriction","DOI":"10.1249\/01.MSS.0000117130.91142.38"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Usefulness of heart-type fatty acid-binding protein and myocardial performance index for early detection of 5-fluorouracil cardiotoxicity","DOI":"10.1177\/0003319716637516"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Pharmacogenomics of fluorouracil-based chemotherapy toxicity","DOI":"10.1517\/17425255.2015.1027684"}],"container-title":["Interventional Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.icrjournal.com\/articleindex\/icr.2019.12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T17:07:56Z","timestamp":1622740076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.icrjournal.com\/articleindex\/icr.2019.12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.15420\/icr.2019.12","relation":{},"ISSN":["1756-1485","1756-1477"],"issn-type":[{"value":"1756-1485","type":"electronic"},{"value":"1756-1477","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,20]]}}}